U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Clinical Review Report: Doravirine (Pifeltro): (Merck Canada Inc.): Indication: Doravirine (Pifeltro) is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults infected with HIV-1 without past or present evidence of viral resistance to doravirine [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jun.

Cover of Clinical Review Report: Doravirine (Pifeltro)

Clinical Review Report: Doravirine (Pifeltro): (Merck Canada Inc.): Indication: Doravirine (Pifeltro) is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults infected with HIV-1 without past or present evidence of viral resistance to doravirine [Internet].

Show details

Abbreviations

3TC

lamivudine

BIC

bictegravir

AE

adverse event

ABC

abacavir

ART

antiretroviral therapy

ARV

antiretroviral

CI

confidence interval

CTAC

Canadian Treatment Action Council

DB

double-blind

DHHS

US Department of Health and Human Services

DTG

dolutegravir

DOR

doravirine

DRV

darunavir

DRV/r

ritonavir-boosted darunavir

DSG

delayed switch group

EFV

efavirenz

EVG

elvitegravir

EQ-5D-5L

EuroQol 5-Dimensions 5-Levels questionnaire

FAS

full-analysis set

FDC

fixed-dose combination

FTC

emtricitabine

HDL

high-density lipoprotein cholesterol

IDC

indirect comparison

InSTI

integrase strand transfer inhibitor

ISG

immediate switch group

IVRS/IVWS

interactive voice/Web response system

LDL

low-density lipoprotein cholesterol

MCID

minimal clinically important difference

NIM

noninferiority margin

NMA

network meta-analysis

NNRTI

non-nucleoside reverse transcriptase inhibitor

NRTI

nucleoside reverse transcriptase inhibitor

OL

open-label

PDVF

protocol-defined virologic failure

PI

protease inhibitor

PP

per-protocol

RCT

randomized controlled trial

RAM

resistance-associated mutation

RNA

ribonucleic acid

SAE

serious adverse event

SD

standard deviation

STR

single-tablet regimen

TAF

tenofovir alafenamide

TDF

tenofovir disoproxil fumarate

ULN

upper limit of normal

WDAE

withdrawal due to adverse event

Copyright © 2019 Canadian Agency for Drugs and Technologies in Health.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK544863

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (1.9M)

Other titles in this collection

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...